![Sture Jan-Gunnar Gustafsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sture Jan-Gunnar Gustafsson
Direktor/Vorstandsmitglied bei Ceffort AB
Profil
Sture Jan-Gunnar Gustafsson is currently working as a Director at Ceffort AB.
Previously, he worked as SVP-Process Development & Manufacturing at Resistentia Pharmaceuticals AB.
He holds an MBA from the University of Stockholm.
Aktive Positionen von Sture Jan-Gunnar Gustafsson
Unternehmen | Position | Beginn |
---|---|---|
Ceffort AB
![]() Ceffort AB BiotechnologyHealth Technology Ceffort AB provides solutions in support for research and development, manufacturing, and business processes. Its common project-based activities includes customer representation; bioprocess development; bioanalytics, sensors, and instrumentation; quality management and documentation; market activities on behalf of customers; due diligence; and competence development. The company was founded by Erik Gunnar Hörnsten in 2009 and is headquartered in Furulund, Sweden. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Sture Jan-Gunnar Gustafsson
Unternehmen | Position | Ende |
---|---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Corporate Officer/Principal | 24.06.2010 |
Ausbildung von Sture Jan-Gunnar Gustafsson
University of Stockholm | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Ceffort AB
![]() Ceffort AB BiotechnologyHealth Technology Ceffort AB provides solutions in support for research and development, manufacturing, and business processes. Its common project-based activities includes customer representation; bioprocess development; bioanalytics, sensors, and instrumentation; quality management and documentation; market activities on behalf of customers; due diligence; and competence development. The company was founded by Erik Gunnar Hörnsten in 2009 and is headquartered in Furulund, Sweden. | Health Technology |